Amylyx Pharmaceuticals (AMLX) Return on Capital Employed Growth (1y) (2023 - 2026)
Amylyx Pharmaceuticals (AMLX) Return on Capital Employed Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 696.00 |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -507.00 |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -723.00 |
| 5 | United Therapeutics | 23.28 Bn | 21.13 Bn | 648.10 Mn | 89.00 |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | 944.00 |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 448.00 |
| 9 | Elanco Animal Health | 12.55 Bn | 12.12 Bn | 785.00 Mn | 1,195.00 |
| 10 | Amylyx Pharmaceuticals | 2.11 Bn | 2.11 Bn | - | 6,849.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,849.00 |
| Dec 31, 2025 | 11,526.00 |
| Sep 30, 2025 | 5,236.00 |
| Jun 30, 2025 | -4,773.00 |
| Mar 31, 2025 | -10,046.00 |
| Dec 31, 2024 | -17,189.00 |
| Sep 30, 2024 | -11,271.00 |
| Jun 30, 2024 | -3,621.00 |
| Mar 31, 2024 | 2,307.00 |
| Dec 31, 2023 | 9,341.00 |
| Sep 30, 2023 | 10,655.00 |
| Jun 30, 2023 | 4,672.00 |
| Mar 31, 2023 | 2,778.00 |